SCHEMBL5229554

SCHEMBL5229554

O=C1CCN(Cc2cccc3ccccc23)C(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR2 P21452 4/20 0.43
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SSTR1 P30872 1/20 0.39
▸ SSTR2 P30874 1/20 0.39
▸ SSTR4 P31391 1/20 0.39
▸ SSTR3 P32745 1/20 0.39
▸ SSTR5 P35346 1/20 0.39
▸ CLPP Q16740 2/20 0.38
▸ PEX14 O75381 1/20 0.38
▸ OPRK1 P41145 2/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ GPR84 Q9NQS5 1/20 0.37
▸ HDAC1 Q13547 2/20 0.37
▸ HDAC8 Q9BY41 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232940 1.00 TACR2 (0.43) TACR2MEN1MAPTKMT2AL3MBTL1
SCHEMBL7094153 0.89 L3MBTL1 (0.43) MEN1MAPTKMT2AL3MBTL1SSTR1
SCHEMBL5239008 0.89 CLPP (0.42) MEN1MAPTKMT2AL3MBTL1SSTR1
SCHEMBL5232904 0.85 TACR2 (0.39) TACR2OPRK1TDP1HDAC1HDAC8
SCHEMBL7536713 0.83 CCR4 (0.37) TACR2MEN1MAPTKMT2AL3MBTL1
SCHEMBL7536717 0.83 CCR4 (0.37) TACR2MEN1MAPTKMT2AL3MBTL1
SCHEMBL5232211 0.83 MEN1 (0.43) TACR2MEN1MAPTKMT2AOPRK1
SCHEMBL5232732 0.81 XIAP (0.37) TACR2MEN1KMT2AOPRK1
SCHEMBL5232741 0.81 XIAP (0.37) TACR2MEN1KMT2AOPRK1
SCHEMBL5237322 0.80 CLPP (0.45) MAPTCLPPPEX14HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP disclosed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 TACR2 7/4885MEN1 687/4885MAPT 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback